Nobel Prize-winning discoveries launched their mission to change lives by changing the course of blood cancer.
As Geron advances towards FDA approval (with their first drug, RYTELO), their website needed to be a flexible, editorial driven experience in support of RYTELO, as well as company leadership, manufacturing, and communications executive to plan, and shape the content to maximize impact, and value.
Geron's brand was enhanced to include a series of custom gradients, and infographics to emphasize their bold nature, and indicate milestones on their journey to commercialization, and beyond.
FDA approved RYTELO on June 6, 2024
Animation was designed to explain how Telomerase operates in the bloodstream. The final video was used to showcase these advancements to investors, and the media, as well as event experiences. R&D Pipeline was reimagined to smoothly flow between the desktop, tablets, and mobile.